Highest-materiality recent filing
Clover Health Q2 2026 GAAP net income $28M, revenue up 56% YoY, raises full-year guidance
Q2 GAAP net income $28M vs loss $10.6M YoY; revenue $743M (+56%).
Clover Health's Medicare Advantage contracts upgraded to 4.5 Stars for payment year 2027
CMS recalculated PPO contract H5141 from 3.5 to 4.5 Stars for payment year 2027 following court judgment.
CMS recalculates Clover's 2026 Star Rating to 4.5 Stars after court ruling
Court granted summary judgment for Clover on May 29, 2026, setting aside the 3.5 Star Rating.
Clover Health posts Q1 GAAP net income of $27M; revenue up 62% YoY
GAAP net income $27.3M vs $(1.3)M in Q1 2025; first positive GAAP net income quarter.
Clover Health CFO Peter Kuipers steps down; Clay Thornton named interim CFO
Peter Kuipers resigns as CFO effective March 30, 2026; will advise through April 24, 2026.
Full year 2025 total revenues of $1.9 billion, up 40% year-over-year; GAAP net loss of $86 million.
Medicare Advantage membership grew 53% YoY to ~153,000 as of Jan 1, 2026, driven by disciplined core-market growth.
Clover Health Q3 revenue up 50% YoY to $497M, but cuts FY25 adjusted EBITDA guidance to $15M-$30M
Q3 GAAP net loss $24.4M; revenue $496.7M vs $331M YoY; membership 109,226 (+35% YoY).
CMS awarded Clover's PPO plans 3.5 Stars and HMO plan 4.0 Stars for 2026 ratings, affecting payment year 2027.
Clover Health Q2 revenue $478M (+34% YoY), membership up 32%, GAAP net loss $11M
Q2 2025 total revenues $477.6M, up 34% YoY; insurance revenue $469.8M (+34.3%).
Clover Health Q1 beat: revenue $462M (+33%), Adj EBITDA $26M (+279%); raises FY guidance
Q1 total revenue $462M, up 33% YoY; GAAP net loss improved to $1M from $19M loss a year ago.
Clover Health FY24 adjusted EBITDA $70M, net loss improves $164M; 2025 revenue guidance $1.8-1.875B
Full year 2024 GAAP net loss from continuing ops narrowed to $46M from $210M in 2023 (improvement of $164M).
Clover Health reports 27% MA membership growth, surpasses 100,000 members after AEP
Medicare Advantage membership grew 27% YoY to over 100,000 as of January 1, 2025.
Clover Health Q3 net loss narrows to $8.8M; raises FY 2024 Adj. EBITDA guidance to $55-65M
GAAP net loss from continuing ops improved to $8.8M from $33.6M YoY; Adjusted EBITDA rose to $19.3M from $2.7M.
Clover Health's PPO Medicare Advantage Plans Earn 4 Star Rating from CMS for 2025
CMS raised Clover Health PPO Medicare Advantage plans to 4 Stars for 2025, affecting payment year 2026.
SEC concludes Clover Health investigation, will not recommend enforcement action
SEC staff notified Clover Health on Sept 26, 2024 that the investigation begun in Feb 2021 is closed.
Clover Health appoints former Molina Healthcare CFO Thomas L. Tran to Board and Audit Committee
Thomas L. Tran appointed Class II director and Audit Committee member; Board expanded from 8 to 9.
Clover Health Q2 2024: first GAAP net income of $7.2M, raises FY2024 guidance
Q2 GAAP net income from continuing operations $7.2M vs. loss of $28.9M in Q2 2023; first positive quarter.
Clover Health regains Nasdaq minimum bid price compliance after 10-day streak above $1.00
Received formal Nasdaq notice on June 26, 2024 that compliance with Listing Rule 5450(a)(1) is regained.
CMS upgrades Clover Health PPO Medicare Advantage Star rating to 3.5 for 2025
CMS recalculated Star rating from 3.0 to 3.5 Stars for 2025 payment year.
Clover Health launches Counterpart Assistant for external payors, expanding SaaS platform
Clover Assistant rebranded as Counterpart Assistant; now generally available to external Medicare Advantage payors and providers.
Clover Health Q1 2024: first Adj. EBITDA profit $6.8M; guides to full-year profitability
Insurance revenue $341.7M (+7.8% YoY); total revenue $346.9M.
Clover Health names Peter Kuipers as CFO; targets adjusted EBITDA profitability in 2024
Peter Kuipers appointed CFO effective after Q1 2024 10-Q filing; succeeds interim CFO Terrence Ronan.
Received Nasdaq notice on April 2, 2024 for CLOV closing below $1.00 for 30 consecutive business days.
Clover Health resolves derivative suits; $2.5M counsel fees, governance changes
Settlement requires no monetary payment to shareholders; $2.5M in fees to plaintiffs' counsel subject to court approval.
Clover Health FY 2023 net loss improves to $213.4M; Insurance MCR drops to 81.2%
Full-year 2023 net loss of $213.4M vs $339.6M in 2022; Insurance MCR improved to 81.2% from 91.8%.
Clover Health targets Adjusted EBITDA profitability for full-year 2024
Targets Adjusted EBITDA profitability for full-year 2024.
Clover Health appoints Terrence Ronan as Interim CFO effective Jan 27, 2024
Ronan will join as Interim SVP of Finance on Jan 2, 2024, then become Interim CFO on Jan 27, 2024 after Scott Leffler's departure.
Clover Health CFO Scott Leffler to depart Jan 26, 2024; FY2023 guidance reiterated
CFO Scott Leffler resigns effective Jan 26, 2024 to pursue another opportunity; no disagreement with company.
Clover Health exits ACO REACH, expects $8M-$10M charges; sees faster path to profitability
Board decided to exit CMS ACO REACH Program; notice delivered Dec 1, 2023, effective end of 2023 performance year.
Clover Health Q3 Adjusted EBITDA loss narrows to $5.1M; raises 2023 guidance
Revenue $482.1M; Insurance revenue up 12% YoY to $301.2M; Non-Insurance revenue down 70% to $176.0M.
On June 15, 2026, Brady Priest notified Clover Health Investments, Corp. (the “Company”) of his decision to step down from his position as Chief Executive Officer of Clover Care Services, the Company’s home-care business, effective as of July 3, 2026.
Mr. Shapiro will fulfill the remainder of his term as member of the Board of Directors and the effective date of his departure will be the Company’s Annual Meeting of Shareholders, June 10, 2025.
On August 20, 2024, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Thomas L. Tran, to serve as a Class II director of the Board.
On April 22, 2024, Clover Health Investments, Corp. (the “Company”) announced that Peter Kuipers will become Chief Financial Officer of the Company, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the day after the filing of the Company’s Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024, as approved by the Board of Directors of the Company on April 16, 2024.
Mr. Kuipers will succeed Terrence Ronan, the Company’s current Interim Chief Financial Officer, who will continue in his role as Interim Chief Financial Officer until Mr. Kuipers becomes Chief Financial Officer, and thereafter cease to serve as the Company’s principal financial officer and principal accounting officer.
following Scott J. Leffler’s previously announced departure as Chief Financial Officer.
On December 22, 2023, the Board of Directors of Clover Health Investments, Corp. (the “Company”) appointed Mr. Terrence Ronan as Interim Chief Financial Officer, including as principal financial officer and principal accounting officer, effective as of January 27, 2024.
On December 15, 2023, Scott J. Leffler notified Clover Health Investments, Corp. (the “Company”) that he will be stepping down as Chief Financial Officer of the Company, including as principal financial officer and principal accounting officer, effective as of January 26, 2024, in order to pursue another professional opportunity.
On June 5, 2023, Joseph Martin notified Clover Health Investments, Corp. (the “Company”) that he will be resigning as General Counsel and Corporate Secretary of the Company, effective as of June 16, 2023, in order to pursue a new role at a public company.
On January 20, 2023, Prabhdeep Singh notified Clover Health Investments, Corp. (the "Company") that he will be stepping down from his position as Chief Growth Officer of the Company, effective March 31, 2023.
On January 6, 2023, the Board of Directors of Clover Health Investments, Corp. (the " Company ") appointed Jamie L. Reynoso Chief Executive Officer of Medicare Advantage, effective immediately.
On November 28, 2022, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Anna Loengard, M.D., to serve as a Class I director of the Board.
Max materiality 0.90 · Median 0.65 · Most common event earnings